The presence of “myeloid” acquired mutations with a higher variant allelic frequency is supportive for the diagnosis of MDS, and the inclusion of STAT3 and STAT5b on the NGS panel provides evaluation for cryptic or unsuspected LGL leukemia [93,94]. This evidence concerns the gene STAT3 and myelodysplastic syndrome.